Patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF) commonly have improvements in their LVEF, but that doesn’t mean they can let their guard down, data from a large ...
Withdrawing renin-angiotensin inhibitors/angiotensin receptor-neprilysin inhibitors and mineralocorticoid receptor antagonists tied to higher one-year mortality, morbidity. HealthDay News — In ...
DALLAS, September 15, 2025 — The American Heart Association, a relentless force changing the future of health for everyone everywhere, is launching a new initiative to improve in-hospital care for ...
Still, the results leave somewhat unclear how different the company’s drug is than marketed hypertrophic cardiomyopathy ...
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ventricular (LV) diastolic function, according to a study published online Sept. 9 ...
The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...
HFpEF and HFmrEF represent up to 75% of heart failure cases, yet treatment evidence is limited compared to other heart failure types. The IMPLEMENT-EF initiative aims to map patient journeys, address ...
The American Heart Association, a relentless force changing the future of health for everyone everywhere, is launching a new initiative to improve in-hospital care for people with heart failure with ...
Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ejection fraction (HFpEF), a type of heart disease that is notoriously difficult ...
Cardiac remodelling encompasses the structural and functional alterations that the myocardium undergoes in response to injury, pressure overload or neurohormonal activation. These changes include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results